This phase I trial tests the safety, side effects, best dose and effectiveness of hypofractionated accelerated radiation therapy (HART) in treating patients with lung cancer receiving chemotherapy. Standard treatment for lung cancer includes treatment with radiation therapy at the same time (concurrent) as chemotherapy. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. HART delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HART concurrent with chemotherapy may be safe, tolerable and/or effective in treating patients with lung cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT06080061.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo AltoStatus: Active
Contact: Lucas Vitzthum
Phone: 650-724-3547
PRIMARY OBJECTIVE:
I. To evaluate the feasibility and safety of a personalized accelerated dosing regimen for patients undergoing concurrent systemic therapy and radiation therapy (RT) for lung cancer.
SECONDARY OBJECTIVES:
I. Evaluate rates of acute and late grade 2 plus (G2+) toxicity including: lung, esophageal, cardiac, chest wall and neurologic.
II. Evaluate the feasibility of integrating an adaptive dosing regimen with an automated planning system.
III. Determine progression free survival, local control, and overall survival in patients treated with hypofractionated radiation therapy with concurrent systemic therapy.
OUTLINE:
Patients undergo HART once daily (QD) on Monday-Friday for 20, 25, or 30 fractions over 4-8 weeks. Patients also undergo computed tomography (CT) scans or positron emission tomography (PET)/CT scans throughout study.
After completion of study treatment, patients are followed up every 3 months for 1 year and then at standard of care visits for up to 3 years.
Lead OrganizationStanford Cancer Institute Palo Alto
Principal InvestigatorLucas Vitzthum
